Filing Analysis
Boundless Bio, Inc. has entered into an amendment to its existing merger agreement with Serapha Bio, Inc. The amendment clarifies terms regarding pre-closing financing, the treatment of Serapha RSUs, and the issuance of pre-funded warrants to avoid beneficial ownership limitations.
🚩 Red Flags
- The amendment addresses 'Pre-Closing Financing,' which may imply ongoing capital requirements or complexities in securing funding prior to the merger's completion.
- The use of pre-funded warrants to circumvent beneficial ownership limits can sometimes indicate complex cap table management or investor-specific structuring.
📋 Key Facts
- Amendment No. 1 to the Merger Agreement between Boundless Bio, Inc. and Serapha Bio, Inc. was executed on August 28, 2026.
- The amendment includes mechanics for converting Serapha RSUs into Assumed RSUs of Boundless Bio common stock.
- Provisions added for the issuance of pre-funded warrants (exercise price $0.00001) to prevent holders from exceeding Beneficial Ownership Limitations.
- The voting standard for increasing authorized shares of Boundless Bio common stock was changed to a majority of shares properly cast, rather than a majority of shares outstanding.
- The merger involves Merger Sub (a wholly owned subsidiary of Boundless Bio) merging into Serapha, with Serapha surviving as a subsidiary.
Boundless Bio, Inc. (BOLD) has entered into a definitive merger agreement with Serapha Bio, Inc., which will result in a reverse takeover where Serapha equityholders will own approximately 96.31% of the combined company. The transaction includes significant financing and requires stockholder approval for several structural changes.
🚩 Red Flags
- Extreme dilution for existing Boundless Bio shareholders (existing holders to own only ~3.69% post-merger).
- Mandatory reverse stock split required as part of the merger terms.
- Significant change in control: Serapha's management and board will take over the combined company.
- The deal is contingent on a PIPE financing of $200M (though only $92M is specifically mentioned in the text, suggesting potential funding gap or ambiguity).
- Lock-up agreements for Serapha executives/directors.
📋 Key Facts
- Merger Agreement entered into on June 22, 2026, between Boundless Bio and Serapha Bio (via Merger Sub).
- Serapha equityholders are expected to own ~96.31% of the combined company; Boundless Bio holders will own ~3.69%.
- The merger is intended to be a tax-free reorganization under Section 368(a).
- Serapha raised $138,000,000 via Series A preferred stock and an additional ~$92,000,000 via a Pre-Closing PIPE financing.
- The transaction is subject to stockholder approval of the merger, a reverse stock split, and an increase in authorized shares.
- Expected closing: Q4 2026.
- Termination fees of $1,000,000 are payable by either party under specific circumstances.
Boundless Bio, Inc. reported the results of its annual meeting of stockholders held on June 15, 2026. The stockholders elected Class II directors and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual meeting of stockholders held on June 15, 2026.
- James Christensen, Ph.D. and Jennifer Lew were elected as Class II directors to serve until the 2029 annual meeting.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 2 (Auditor ratification) received 15,376,973 votes in favor and 127,747 votes against.
Boundless Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as an exhibit to the filing.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended March 31, 2026.
- The filing was made on May 8, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information in the press release (Exhibit 99.1) is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Boundless Bio is an emerging growth company as defined in Rule 405.
Boundless Bio, Inc. entered into an agreement to terminate its 80,168 square foot laboratory and office lease in San Diego effective May 31, 2026, more than eight years ahead of the original 2034 expiration date. The company will incur a $10.0 million termination payment and forfeit a $0.5 million security deposit to exit the agreement.
🚩 Red Flags
- Significant cash outflow of $10.5 million for a non-operational expense.
- Abrupt exit from a long-term facility commitment eight years early, suggesting a major pivot or downsizing.
- Forfeiture of the entire security deposit.
📋 Key Facts
- Lease termination for 80,168 rentable square feet at 10955 Alexandria Way, San Diego.
- The lease was originally scheduled to expire on October 31, 2034.
- The company must pay a $10.0 million lease modification payment.
- The landlord will retain the full $0.5 million security deposit.
- The termination was contingent on the landlord securing a new tenant, a condition that has been satisfied.
- The effective termination date is May 31, 2026.
Boundless Bio, Inc. reported its Q4 and full-year 2025 financial results and announced the resignation of board member Dr. Christine Brennan. Dr. Brennan's departure is effective March 3, 2026, and is not due to any disagreement with the company.
📋 Key Facts
- Financial results for the fourth quarter and full year ended December 31, 2025, were released on March 9, 2026.
- Dr. Christine Brennan resigned from the Board of Directors effective March 3, 2026.
- The resignation is attributed to Dr. Brennan assuming a new role at Johnson & Johnson Development Corporation.
- The company stated there were no disagreements regarding operations, policies, or practices.
Boundless Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: November 05, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Company is an emerging growth company
Boundless Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal announcement of the release of the company's earnings press release.
📋 Key Facts
- The report date is August 5, 2025.
- The filing pertains to financial results for the quarter ended June 30, 2025.
- The company issued a press release (Exhibit 99.1) containing the earnings data.
- Boundless Bio, Inc. is an emerging growth company.
Boundless Bio, Inc. reported the results of its annual meeting of stockholders held on June 23, 2025. The meeting included the election of Class I directors and the ratification of KPMG LLP as the independent auditor for fiscal year 2025.
📋 Key Facts
- Annual meeting held on June 23, 2025.
- Proposal 1: Election of Christine Brennan, Ph.D. and Nancy Whiting, Pharm.D. to Class I director positions until the 2028 annual meeting.
- Proposal 2: Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
- KPMG LLP received significant support with 17,791,309 votes in favor.
Boundless Bio, Inc. announced a significant workforce reduction of approximately one-third of its staff to facilitate portfolio prioritization and cost management. The company is discontinuing certain clinical trial arms for BBI-355 due to toxicity issues and shifting focus toward a combination therapy approach and its Kinesin program.
🚩 Red Flags
- Significant workforce reduction (one-third of staff) indicating operational restructuring/downsizing.
- Clinical failure/pivot: Discontinuation of BBI-355 single-agent development due to toxicity and suboptimal dosing profiles.
- One-time charges of $1.2 million expected in Q2 2025.
📋 Key Facts
- Workforce reduction of approximately one-third of the Company's total workforce.
- Expected one-time termination costs of approximately $1.2 million, primarily related to severance and healthcare benefits.
- Discontinuation of current arms of the POTENTIATE clinical trial for BBI-355 as a single agent due to narrow therapeutic index and hematological toxicity.
- Strategic shift to develop BBI-355 and BBI-825 as a combination therapy in 2025.
- Reaffirmed Kinesin program (BBI-940) with expected IND application submission in H1 2026.
- Cash, cash equivalents, and short-term investments totaled $138.3 million as of March 31, 2025.
- Projected cash runway extended into the first half of 2028.
Boundless Bio, Inc. issued an 8-K to furnish its quarterly financial results for the period ended March 31, 2025 via a press release.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing is intended to satisfy the requirements of Item 2.02 regarding Results of Operations and Financial Condition.
- Information was furnished via press release (Exhibit 99.1) rather than filed.
Boundless Bio, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to facilitate 'at-the-market' (ATM) offerings of common stock up to a total aggregate price of $14.5 million.
🚩 Red Flags
- Potential for significant shareholder dilution through the ATM offering.
- The use of an ATM facility often indicates a need for immediate liquidity to fund operations.
📋 Key Facts
- Entered into Sales Agreement with Jefferies LLC on April 1, 2025.
- Aggregate offering size: up to $14.5 million in common stock.
- Sales will be made at prevailing market prices via an ATM offering.
- Agent (Jefferies) receives a commission of up to 3.0% of gross proceeds.
- Shares to be issued under a shelf registration statement on Form S-3 filed April 1, 2025.
Boundless Bio, Inc. issued an 8-K to furnish its press release announcing financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2024.
- Filing date: March 27, 2025.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Boundless Bio, Inc. announced the departure of its Chief Medical Officer, Klaus Wagner, M.D., Ph.D., effective December 29, 2024. The company also issued updates regarding its ecDNA directed therapy (ecDTx) pipeline and provided a positive cash runway outlook.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a biotech company can signal internal shifts or challenges in clinical development leadership.
📋 Key Facts
- Klaus Wagner, M.D., Ph.D., is stepping down as Chief Medical Officer effective December 29, 2024.
- The company issued updates on its extrachromosomal DNA (ecDNA) directed therapy (ecDTx) programs via press release on December 12, 2024.
- Management stated that current cash, cash equivalents, and short-term investments are expected to fund operations into 2027.
Boundless Bio, Inc. issued an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the press release containing these results.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- The company is an emerging growth company
- Financial results were issued via press release (Exhibit 99.1)
Boundless Bio, Inc. announced the departure of its CFO and Treasurer, Jami Rubin, effective October 11, 2024. David Hinkle has been appointed to serve as the interim Principal Financial Officer, Treasurer, and Principal Accounting Officer.
🚩 Red Flags
- Sudden departure of a key executive (CFO) can sometimes signal internal friction or financial irregularities, though no restatement was noted here.
- Interim appointment of the Controller as CFO suggests a potential gap in leadership continuity during a critical phase.
📋 Key Facts
- Jami Rubin stepped down as CFO and Treasurer effective October 11, 2024.
- The departure is characterized as a termination of employment other than for Cause.
- David Hinkle (SVP, Finance & Controller) appointed as interim Principal Financial Officer, Treasurer, and Principal Accounting Officer.
- Ms. Rubin is entitled to severance benefits under the Company's Severance and Change in Control Severance Plan, subject to a waiver and release of claims.
Boundless Bio, Inc. announced a repricing of outstanding stock options for certain employees, including named executive officers, effective August 19, 2024. The exercise price was reduced from $3.71+ to the current market price of $3.56 per share.
🚩 Red Flags
- Option repricing for named executive officers often signals significant downward pressure on stock price and loss of employee motivation at previous strike prices.
- The reduction in exercise price is a form of backdated compensation that can be viewed negatively by the market as it dilutes existing shareholders to benefit insiders.
📋 Key Facts
- Repricing effective date: August 19, 2024.
- Exercise price reduction: From $3.71 or greater down to $3.56 per share (the closing price on Aug 19, 2024).
- CEO Zachary D. Hornby received repriced options for 1,147,242 shares.
- CMO Klaus Wagner received repriced options for 316,893 shares.
- CSO Chris Hassig received repriced options for 292,821 shares.
- Repricing is subject to a service condition through the 'Premium End Date' (earliest of Aug 19, 2026, change in control, or Qualifying Termination).
Boundless Bio, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Boundless Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2024 and provided an updated corporate presentation on its investor relations website.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2024 via press release (Exhibit 99.1).
- Updated the company's corporate presentation on its investor relations website.
- The filing includes a notice that future updates to the corporate presentation will be made via the website rather than individual 8-K filings.
Boundless Bio, Inc. successfully completed its initial public offering (IPO) on April 2, 2024. The company issued 6,250,000 shares at $16.00 per share, raising approximately $100 million in gross proceeds.
🚩 Red Flags
- Increased difficulty for stockholders to remove directors (requires 2/3 vote and 'for cause' justification).
- Elimination of the ability for stockholders to take action via written consent.
- Establishment of exclusive forum provisions in Delaware for certain legal actions.
📋 Key Facts
- Completed IPO of 6,250,000 shares of common stock.
- Public offering price was $16.00 per share.
- Gross proceeds totaled $100.0 million (before underwriting discounts and expenses).
- Amended and Restated Certificate of Incorporation filed to increase authorized common stock to 700,000,000 shares.
- Authorized 70,000,000 shares of undesignated preferred stock.
- Established a classified board of directors with three-year staggered terms.
- Implemented provisions for director removal only 'for cause' by a two-thirds vote.